Ammonia: A novel target for the treatment of Non-Alcoholic Steatohepatitis

MD, PhD Karen Louise Thomsen¹ ², PhD Francesco De Chiara¹, PhD Krista Rombouts¹, MD, DSc Hendrik Vilstrup², PhD Fausto Andreola¹, MBBS, PhD, FRCP Rajeshwar P Mookerjee¹, MBBS, PhD, FRCPE Rajiv Jalan¹

¹ UCL Institute for Liver and Digestive Health, University College London, United Kingdom
² Department of Hepatology & Gastroenterology, Aarhus University Hospital, Denmark

Correspondence and requests for offprints:
Professor Rajiv Jalan
UCL Institute of Liver and Digestive Health
University College London
Royal Free Campus
Rowland Hill Street
London NW32PF
United Kingdom
Phone (direct): +44 2074332795
E-mail: r.jalan@ucl.ac.uk

Sources of support
This study was generously supported by grants from the Novo Nordisk foundation and the Danish Council for Independent Research.
SUMMARY

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver diseases ranging from steatosis, through non-alcoholic steatohepatitis (NASH) to cirrhosis. The development of fibrosis is the most important factor contributing to NASH-associated morbidity and mortality. Hepatic stellate cells (HSCs) are responsible for extracellular matrix deposition in conditions of frank hepatocellular injury and are key cells involved in the development of fibrosis. In experimental models and patients with NASH, urea cycle enzyme gene and protein expression is reduced resulting in functional reduction in the in vivo capacity for ureagenesis and subsequent hyperammonemia at a pre-cirrhotic stage. Ammonia has been shown to activate HSCs in vivo and in vitro. Hyperammonemia in the context of NASH may therefore favour the progression of fibrosis and the disease. We therefore hypothesise that ammonia is a potential target for prevention of fibrosis progression of patients with NASH.
INTRODUCTION
The WHO estimates over 650 million people globally and more than 29 million Europeans have chronic liver disease [1]. Alarming increases in obesity rates and in tandem, increases in rates of non-alcoholic fatty liver disease (NAFLD), plus an ageing population mean that liver disease will become an even greater health concern over the next decade [2]. NAFLD is a spectrum of liver disease ranging from steatosis, through non-alcoholic steatohepatitis (NASH) to cirrhosis, and possible hepatocellular carcinoma. The prognosis of patients with simple steatosis appears good whereas NASH often has a progressive course with increased liver-related morbidity and mortality [3-5]. Given the increasing population prevalence of NAFLD and NASH, the ability to treat NASH would be a significant clinical breakthrough. Treatment options for NASH are limited to life-style modifications with no approved targeted drug therapy available. This article focuses on recent studies that provide the basis for proposing targeting of ammonia as a new therapeutic approach for NASH.

BACKGROUND
NAFLD is a condition characterized by fatty acid uptake, *de novo* fatty acid synthesis and reduced beta-oxidation leading to increased liver fat in patients that are not consuming excessive alcohol. The pathophysiological diagnosis of NASH refers to the presence of histological inflammation, pericellular fibrosis and liver injury super imposed on vesicular fat laden hepatocytes characteristic of NAFLD [6]. Recently, NASH has been defined as a “multiple parallel hits” disease that can progress to liver fibrosis, which develops primarily in the pericentral areas, surrounding groups of hepatocytes and thickening of the space of Disse with eventual nodule formation [7]. The development of advanced fibrosis is the
most important factor contributing to NASH-associated morbidity and mortality [8]. The main cell type responsible for extracellular matrix deposition are hepatic stellate cells (HSC), that undergo activation in conditions of frank hepatocellular injury, enabling them to participate in the wound healing process [9]. HSCs are key in maintaining architectural integrity and in the development of fibrosis, portal hypertension and liver cancer [10-12] and reduction in their activation is a target for therapy.

The Urea cycle, as a complete process running exclusively in the liver, has evolved in mammals to ultimately remove ammonia through conversion of excess amino-nitrogen to urea. The cycle comprises 5 enzymes, the first and the last of which reside in the mitochondria - cabamoylphosphate synthetase (CPS) and ornithine transcarbamoylase (OTC) [13]. In liver failure patients, ammonia accumulates through reduction in the function of the urea cycle due to a reduction in liver cell mass, producing numerous deleterious effects ranging from hepatic encephalopathy to neutrophil dysfunction and loss of muscle mass [14-17]. Genetic OTC deficiency is the most common type of inherited urea cycle enzyme deficiency disease and is manifest by catastrophic hyperammonemia and hepatic encephalopathy. In the adult form of OTC deficiency, milder degrees of hyperammonemia are manifest [18].

In NASH, many lines of investigation indicate that mitochondria are dysfunctional [19] and it is, therefore, possible that the resultant mitochondrial injury may affect CPS and OTC function, and in turn, result in compromised urea synthesis capacity and ultimately hyperammonemia. As mitochondria are mandatory for the production of cellular energy through β-oxidation of fatty acids, disruption in their function is often accompanied by an
enhanced production of reactive oxygen species (ROS), which mediates a pro-inflammatory microenvironment, promoting further liver injury.

Emerging data suggests a link between NASH, reduction in gene expression and function of urea cycle enzymes, resulting in hyperammonemia and progression of liver injury and fibrosis. This supports a rationale for targeting ammonia as a potential treatment for NASH. The mechanism is likely to be specific for liver disease in which triglycerides accumulate in hepatocytes and the liver becomes steatotic thereby reducing the function of urea synthesis leading to hyperammonemia at a pre-cirrhotic stage. Long-chain fatty acids promote perturbations in urea cycle enzyme gene expression resulting in hyperammonemia [20], whereas hepatic triglyceride accumulation (as is the case in NASH) is known to inhibit ureagenesis and increase ammonia concentrations around perivenous hepatocytes [21]. Hyperammonemia is associated with alteration of several genes including the Toll-like receptor pathway and increased hepatocyte apoptosis [22]. In urea cycle enzyme knock out mice, induction of chronic liver injury leads to increased oxidative stress, impaired fatty acid β-oxidation and enhanced liver injury compared to wild type mice [23] and likewise, livers from patients with urea cycle disorders, including OTC deficiency, demonstrate extensive hepatic fibrosis and cirrhosis [24].

OBSERVATIONS LEADING UP TO THE HYPOTHESES

Evidence that NASH results in hyperammonemia and a reversible reduction in activity and function of urea cycle enzymes

1. We have previously shown experimentally that diet-induced NASH in rats reduces CPS and particularly OTC gene and protein expression resulting in functional reduction in the in
vivo capacity for ureagenesis [25]. This impairs nitrogen homeostasis and results in hyperammonemia at a non-cirrhotic stage, Figure 1A and B. A follow-on study demonstrated that these changes were reversible upon recovery from NASH, and that reversal of NASH by reversion of the fat diet to normal chow, restored CPS and OTC gene and protein expression [26].

2. In another experimental model of NASH (methionine-choline deficient (MCD) mice), we demonstrated reduced OTC gene expression and showed that reducing the level of bacterial translocation through mesoporous carbons [27], prevents NASH and restores OTC gene expression. This suggests that inflammation in NASH contributes to depression of OTC gene expression and that functionality of OTC can be restored [26], Figure 2.

3. Importantly, in humans, NASH is also associated with reduced gene and protein expression of urea cycle enzymes. Data from human microarray shows that all the key urea cycle enzymes are down-regulated in the livers of patients with NASH, with OTC showing a >2 fold reduction compared to normal liver (Prof Ramon Bataller – personal communication). Furthermore, in NAFLD patients who had a liver biopsy obtained during bariatric surgery, those with NASH and fibrosis had significantly lower OTC gene expression than patients with steatosis alone [26], Figure 3A and increased ammonia concentrations in liver tissue, Figure 3B.

4. The reduced urea cycle enzyme expression in patients with NASH gives rise to a reduced ammonia clearance. In patients with biopsy-proven, non-cirrhotic NASH. Felipo et al. found higher plasma ammonia levels compared to patients with simple steatosis and
age-matched controls [28]. Additionally, these non-cirrhotic NASH patients showed evidence of neuropsychiatric disturbances that are commonly associated with hyperammonemia in the context of cirrhosis.

Evidence that ammonia produces functional and morphological changes in human HSCs

Pathological levels of ammonia are known to induce metabolic effects and cell swelling in astrocytes in the brain, which is central in the pathogenesis of hepatic encephalopathy [29]. Several studies have indicated that astrocytes and HSCs share a similar mesodermal origin and express similar cell markers of activation [30, 31]. We have recently demonstrated that pathological ammonia concentrations (50-300uM) produce changes in human HSC behaviour including significant alterations in cellular morphology (cytoplasmic vacuolisation, ER enlargement), reactive oxygen species production and induction of further HSC activation. Removal of ammonia from the cultures restored HSC morphology and function towards normality indicating that the ammonia-induced changes in HSCs are reversible [32], Figure 4.

Evidence that reduction of ammonia concentration in vivo reduces stellate cell activation and reduces portal hypertension

We undertook an in vivo study to establish if the ammonia scavenging drug ornithine phenylacetate (OP) was able to prevent the activation of HSC. Four-week bile duct ligated rats with advanced fibrosis and hyperammonemia were treated with OP and we observed reduced plasma ammonia, abrogated tissue markers of HSC activation and significantly
reduced portal pressure indicating that targeting ammonia \textit{in vivo} reduces HSC activation and may also be beneficial for treatment of portal hypertension [32], Figure 5.

THE HYPOTHESIS

The data presented above shows that NASH produces a reversible reduction in the expression and function of urea cycle enzymes resulting in decreased ammonia elimination and ultimately hyperammonemia at a non-cirrhotic stage. Ammonia produces morphological changes and further activation of HSCs, which, in the context of NASH, by means of their pro-fibrotic and pro-inflammatory potential, may favour the progression of NASH. It follows that ammonia scavenging may represent a therapeutic target in NASH, Figure 6.

	extit{Hypothesis:}

1. Administration of an ammonia-lowering drug in NASH reduces disease progression through non-urea ammonia scavenging and thereby reduction in activation of HSCs.

DISCUSSION

Our hypothesis provides the rationale for targeting ammonia as a potential treatment for NASH. We suggest that hyperammonemia is present in NASH at the non-cirrhotic stage and that ammonia is an important molecule involved in the progression towards development of fibrosis. We believe this mechanism is specific for steatotic liver diseases and ammonia scavenging could therefore also be an anti-fibrotic therapy in e.g. alcoholic steatohepatitis. In contrast, in patients with decompensated cirrhosis ammonia lowering is
a strategy for the treatment of hepatic encephalopathy. Extra cerebral effects of ammonia have not been fully appreciated [14, 33]. More recently, pathophysiological concentrations of ammonia were shown to result in neutrophil dysfunction both in vivo and in vitro [16]. Also, Dasarathy et al. have shown that ammonia is important in the muscle metabolism and may be a target to treat sarcopenia [34]. OP has been proven to reduce ammonia levels in animals with acute-on-chronic and acute liver failure [35, 36], and our findings indicate that this may also reduce activation of HSCs [32]. Preliminary data from our own laboratories have shown similar results in a NASH animal model [37]. Also in humans, OP is considered safe and beneficial as an ammonia scavenger to treat hyperammonemia in healthy subjects and patients with cirrhosis [38]. Therefore, the potential for early translation to test our hypothesis in NASH patients is not far away, especially as other ammonia lowering agents e.g. lactulose are already used as standard-of-care in the prevention and treatment of hyperammonemia and hepatic encephalopathy in cirrhotic patients.
ACKNOWLEDGEMENTS

This study was generously supported by grants from the Novo Nordisk foundation and the Danish Council for Independent Research. Sponsors had no involvement in collection, analysis or interpretation of data.
REFERENCES


[34] Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol 2016;65:1232-1244.


FIGURE CAPTIONS

Figure 1. Capacity of urea nitrogen synthesis (CUNS) (A) and liver ammonia concentrations (B) in control and NASH animals.

Changes in the in vivo capacity of urea nitrogen synthesis (CUNS) in animals fed a standard diet (controls) or a high-fat high-cholesterol (HFC) diet for 4 (early NASH) and 16 (advanced NASH) weeks. Bars represent the mean and SEM. * P=0.01 compared to controls (A). Ammonia concentrations in liver tissue from animals fed a standard diet (controls) or a HFC diet for 16 weeks assessed using Nessler’s reagent [39]. In controls, ammonia is present in red blood cells only (pale-yellow, black arrows). In HFC-fed animals, ammonia is diffusively scattered in the hepatic parenchyma and tends to accumulate in the walls of vessels (black arrows) (B).

Footnote: Figure 1A: Reprinted from Am J Physiol Gastrointest Liver Physiol, 307, Thomsen KL, Grønbæk H, Glavind E, Hebbard L, Jessen N, Clouston A, George J, Vilstrup H. Experimental non-alcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function, G295-G301, Copyright (2014), with permission from the American Physiological Society.

Figure 2. H&E staining of liver tissue and ornithine transcarbamylase mRNA levels in controls and methionine-choline deficient mice with and without carbon treatment.

Representative H&E stain of liver tissue and ornithine transcarbamylase (OTC) mRNA levels from controls and from methionine-choline deficient (MCD) mice with and without treatment with mesoporous carbons (Yaq-001). Results from MCD mice are presented as relative levels compared to controls. Bars represent the mean and SD. ** P<0.01.
Figure 3. Ornithine transcarbamylase mRNA levels in patients with steatosis and NASH (A) and liver ammonia concentrations in healthy controls and NASH patients (B).

Ornithine transcarbamylase (OTC) mRNA levels in the liver from patients with simple steatosis and patients with NASH. Results are presented as relative levels compared to GAPDH. The solid horizontal lines indicate the mean values and the bars SD. The OTC mRNA levels are decreased in patients with NASH compared with simple steatosis (P=0.05) (A). Ammonia concentrations in liver tissue from healthy controls and in patients with NASH assessed using Nessler’s reagent [39]. Black arrows point to ammonia. In NASH patients, the ammonia tends to accumulate in the cytoplasm of the hepatocytes (pale yellow) on occasion in very high concentrations (black spot). L indicates lipid droplets (B).

Figure 4. Ammonia causes alterations in cellular morphology, reactive oxygen species (ROS) production and induction of human stellate cell (HSC) activation.

(A) Transmission Electron Microscopy shows that ammonia causes dramatic morphological changes in a dose-dependent manner, with appearance of cytoplasmic vacuolisation and ER enlargement. (B) Mean fluorescence intensity (MFI) of ROS signal is normalized according to the number of cells and expressed as percentage of control. Bar graphs show means of three independent values ± SD. *** P<0.001 vs. corresponding values of SFM. (C) Ammonia affects protein expression of the HSC activation markers α-SMA, myosin IIa and IIb, PDGFRβ and vinculin.
Figure 5. Plasma ammonia, tissue markers of human stellate cell (HSC) activation and portal pressure in bile duct ligated (BDL) rats following ornithine phenylacetate (OP) treatment.

(A) Plasma levels of ammonia are significant upregulated in BDL and amino acids (AAs)-fed BDL animals in comparison to sham-operated rats (* P<0.05 and ** P<0.01 vs. sham). OP treatment reduces significantly ammonia levels in BDL-AAs-fed animals in comparison to BDL animals (** P<0.01). (B) Hyperammonemia treatment in BDL-induced fibrosis shows an additional significant increase in myosin IIb, collagen type I and PDGFRβ protein expression in comparison to BDL-induced fibrosis. In contrast, treatment with OP abrogates the strong effect of AAs-fed BDL on all HSC-related activation markers. (C) Portal pressure is increased in BDL rats compared to sham (*** P<0.001). Administration of OP results in a significant lowering of portal pressure compared to BDL saline-treated rats (* P<0.01).

Footnote: Figure 4 and 5: Reprinted from J Hepatol, Vol 64, Jalan R, De Chiara F, Balasubramaniyan V, Andreola F, Khetan V, Malago M, Pinzani M, Mookerjee RP, Rombouts K. Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension, 823-833, Copyright (2016), with permission from Elsevier.

Figure 6. Schematic showing NASH induces hyperammonemia resulting in activation of human hepatic stellate cells (HSCs)

NASH produces a reversible reduction in the expression and function of urea cycle enzymes, resulting in a functional reduction in in vivo capacity for ureagenesis. The resulting hyperammonemia activates HSCs generating both morphological changes and pro-fibrotic and pro-inflammatory factors that may favour the progression of NASH. It follows that ammonia scavenging may represent a therapeutic target in NASH.
Figure 1A

[Graph showing a comparison of CUNS (μmol x min⁻¹ x 100g⁻¹) levels between controls and NASH patients at 4 weeks and 16 weeks. The graph indicates a significant difference (*) between controls and advanced NASH at 16 weeks.]
Figure 2
Figure 3A

[Graph showing mRNA expression (OTC/GAPDH) for Steatosis and NASH groups. The graph indicates a statistically significant difference (P=0.05) between the two groups.]
Figure 4

A

CM

SFM

50 µM

100 µM

300 µM

8000x

20 000x

B

Fluorimetric quantification of ROS production

MFI (ROS:Hoechst)[% Control]

CM SFM 50µM 100µM 300µM

C

α-SMA

Myosin IIa

Myosin IIb

PDGF-Rβ

Vinculin

μM Ammonia

CM SFM 50 100 300
Figure 6